{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T08:14:56Z","timestamp":1769933696314,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Genetics and Cytogenetics"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.cancergencyto.2010.08.006","type":"journal-article","created":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T10:25:04Z","timestamp":1292322304000},"page":"169-175","source":"Crossref","is-referenced-by-count":16,"title":["Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma"],"prefix":"10.1016","volume":"203","author":[{"given":"Ulrike","family":"Bacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Kern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Alpermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Schnittger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergencyto.2010.08.006_bib1","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib2","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.4065\/82.12.1468","article-title":"Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana","volume":"82","author":"Landgren","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib3","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.4065\/82.12.1474","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan","volume":"82","author":"Iwanaga","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib5","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/leu.2008.203","article-title":"Pathogenesis and progression of monoclonal gammopathy of undetermined significance","volume":"22","author":"Blade","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib6","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib7","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2009.122","article-title":"International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation","volume":"23","author":"Palumbo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib8","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.leu.2403586","article-title":"Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma","volume":"19","author":"Wuilleme","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.leu.2404172","article-title":"Prognostic factors for hyperdiploid-myeloma: effects of hromosome 13 deletions and IgH translocations","volume":"20","author":"Chng","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1586\/14737159.7.4.453","article-title":"Review of molecular diagnostics in multiple myeloma","volume":"7","author":"Stewart","year":"2007","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood-2008-12-193458","article-title":"Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13","volume":"114","author":"Reece","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3816\/CLM.2007.n.003","article-title":"Sequential analysis of chromosome aberrations in multiple myeloma during disease progression","volume":"7","author":"Wu","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib14","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib15","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib16","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib17","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1158\/1078-0432.CCR-07-0031","article-title":"Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients","volume":"13","author":"Brousseau","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2141.2004.05060.x","article-title":"High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation","volume":"126","author":"Nilsson","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2141.2002.03651.x","article-title":"Long-term follow up with conventional cytogenetics and band 13q14 interphase\/metaphase in situ hybridization monitoring in monoclonal gammopathies of undetermined significance","volume":"118","author":"Bernasconi","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib20","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood.V94.8.2583.420a05_2583_2589","article-title":"Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome","volume":"94","author":"Avet-Loiseau","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib21","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2009.011064","article-title":"Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib22","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/cncr.11100","article-title":"Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia","volume":"97","author":"Rasillo","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib24","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/leu.2009.160","article-title":"The molecular characterization and clinical management of multiple myeloma in the post-genome era","volume":"23","author":"Zhou","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib25","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib26","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic significance of copy-number alterations in multiple myeloma","volume":"27","author":"Avet-Loiseau","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib28","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1182\/blood-2007-11-120535","article-title":"Flow cytometric immunophenotyping for hematologic neoplasms","volume":"111","author":"Craig","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib29","doi-asserted-by":"crossref","first-page":"951","DOI":"10.5858\/2007-131-951-QOPCIB","article-title":"Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment","volume":"131","author":"Smock","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib30","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2141.2006.06068.x","article-title":"Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration","volume":"133","author":"Nadav","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib31","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib32","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","article-title":"Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy","volume":"26","author":"Mateo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/107327489800500301","article-title":"Biology of the transition of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma","volume":"5","author":"Lust","year":"1998","journal-title":"Cancer Control"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib34","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1158\/1078-0432.CCR-09-1575","article-title":"Prevention of progression in monoclonal gammopathy of undetermined significance","volume":"15","author":"Rajkumar","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib35","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1158\/1078-0432.CCR-08-2217","article-title":"The potential role of curcumin in patients with monoclonal gammopathy of undefined significance\u2014its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker","volume":"15","author":"Golombick","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cancergencyto.2006.11.015","article-title":"Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark","volume":"15","author":"Christensen","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2010.08.006_bib37","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/sj.leu.2404459","article-title":"Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion","volume":"21","author":"Sagaster","year":"2007","journal-title":"Leukemia"},{"issue":"suppl 4","key":"10.1016\/j.cancergencyto.2010.08.006_bib38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/annonc\/mdp140","article-title":"Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Harousseau","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Cancer Genetics and Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460810004474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460810004474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T11:12:14Z","timestamp":1636974734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165460810004474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0165460810004474"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergencyto.2010.08.006","relation":{},"ISSN":["0165-4608"],"issn-type":[{"value":"0165-4608","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}